The Value of Stillness
Health Care: Drugs
Onyx Pharmaceuticals Inc. (ONXX: NASDAQ)
$88.80 -1.18 | -1.31%
06/18/13 - 04:00 PM ET
Portfolios with ONXX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor4 Drug Stocks Facing FDA Ap...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- Userplayers
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
Latest ONXX Headlines from TheStreet
- Onyx Reaches New 52-Week High (ONXX) 04.10.13 | 10:04 am
- Market Takes Aim at Historic Highs Once Again
04.10.13 | 09:04 am - Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX 04.05.13 | 06:04 am
- Onyx Pharmaceuticals Inc. (ONXX): Drugs' Highlighted Dud Of The Day 04.04.13 | 05:04 pm
- 8 Stocks Surging on Big Volume 04.01.13 | 03:04 pm
- Analysts' Actions: INTC ONXX VRSN Z RHAT 03.28.13 | 09:03 am
- Onyx Pharmaceuticals Inc. (ONXX): Today's Highlighted Performer In Drugs 03.25.13 | 05:03 pm
- 8 Stocks With Buy Ratings From Deutsche Bank And UBS 03.14.13 | 01:03 pm
- Onyx Rises On Unusually High Volume (ONXX) 03.07.13 | 04:03 pm
- The Next Big Thing In Biotech: Onyx 03.07.13 | 01:03 pm
Press Releases for ONXX
- Phase 3 DECISION Trial Investigating The Use Of Nexavar® (sorafenib) Demonstrated Significant Improvement In Progression-Free Survival In Patients With Radioactive Iodine-Refractory Differentiated Thyroid Cancer - PR Newswire 06.02.13 | 07:06 am
- Bayer's Stivarga® (regorafenib) Tablets Approved In Japan - PR Newswire 03.25.13 | 05:03 pm
- Bayer's Stivarga® (regorafenib) Tablets Approved By U.S. FDA For Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic GIST - PR Newswire 02.25.13 | 04:02 pm
- Onyx Pharmaceuticals Launches Make Your Mark At The Multiple Myeloma Experience To Champion Progress In Multiple Myeloma Research And Treatment - PR Newswire 12.06.12 | 04:12 pm
- Onyx Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire 09.04.12 | 04:09 pm
- Bayer Submits New Drug Application For Regorafenib For The Treatment Of Gastrointestinal Stromal Tumors (GIST) - PR Newswire 08.30.12 | 10:08 am
- Onyx Pharmaceuticals Announces Kyprolis⢠Study Published In The Medical Journal Blood - PR Newswire 07.25.12 | 09:07 am
- Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012 - PR Newswire 07.23.12 | 04:07 pm
- Addition Of Tarceva® (erlotinib) To Nexavar® (sorafenib) Did Not Provide Additional Benefit To Patients With Unresectable Liver Cancer Versus Nexavar Alone In Phase 3 Trial - PR Newswire 07.23.12 | 02:07 am
- Onyx Pharmaceuticals Receives FDA Accelerated Approval Of Kyprolis⢠(carfilzomib) For Injection - PR Newswire 07.20.12 | 12:07 pm
Partner Headlines for ONXX
- Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB) - Benzinga 06.12.13 | 01:06 pm
- Onyx Phase 3 Nexavar DECISION Trial Shows Significant Improvement in Progression-Free Survival in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer - Benzinga 06.02.13 | 09:06 am
- Onyx Pharma to Hold Call to Discuss Phase 3 DECISION Data at 2013 ASCO - Benzinga 05.31.13 | 04:05 pm
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy - NASDAQ 05.07.13 | 05:05 pm
- Onyx Pharmaceuticals Earnings: Here’s Why Investors are Buying Shares Now - Wall St. Cheat Sheet 05.07.13 | 06:05 am
- Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick - NASDAQ 04.26.13 | 07:04 pm
- Deutsche Bank Reiterates Buy on Onyx Pharmaceuticals on Updated Guidelines - Benzinga 03.11.13 | 01:03 pm
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- Onyx Pharmaceuticals (ONXX) - Bull of the Day - Zacks 12.05.12 | 01:12 am
